Showing 8231-8240 of 8821 results for "".
- New Tattoo Survey Shows Tattoo Acceptance Up; Tattoo Regret Still an Issuehttps://practicaldermatology.com/news/new-tattoo-survey-shows-tattoo-acceptance-up-tattoo-regret-still-an-issue/2458826/With nearly 40 percent of Americans ages 18-29 sporting ink, body art has not only become mainstream, but can actually up someone's stock. In a recent Syneron Candela survey, attitudes toward people with tattoos were overwhelmingly positive, being described as artistic and creative (50 percen
- Revance Reports Positive 6-Month Duration for RT002 in BELMONT Studyhttps://practicaldermatology.com/news/revance-reports-positive-6-month-duration-for-rt002-in-belmont-study/2458831/Revance Therapeutics, Inc., shared positive 24-week results from its multi-center BELMONT Phase 2 active comparator study of injectable RT002. The ongoing study for the treatment of glabellar lines in 268 subjects compared the safety, efficacy, and duration of effect of three doses of RT002
- Now Available at Pharmacies: Bayer's Finacea® Foam 15%https://practicaldermatology.com/news/now-available-at-pharmacies-bayers-finacea-azelaic-acid-foam-15/2458835/Bayer HealthCare’s Finacea® (azelaic acid) Foam, 15% in now available at pharmacies nationwide. Finacea Foam was FDA approved in July 2015 for the topical treatment of the inflammatory papules and pustules of mild to moderate rosacea. The approval was based on results
- Zwivel and CareCredit Team Uphttps://practicaldermatology.com/news/zwivel-and-carecredit-team-up/2458836/CareCredit, a provider of patient financing, and Zwivel, an online cosmetic consultation platform that enables cosmetic patients and doctors to interact prior to an in-office consultation, signed a marketing agreement enabling consumers to apply for a CareCredit health, wellness, and beauty credi
- Phase 2 Psoriasis Study Shows Positive Results for Boehringer Ingelheim's Investigational Biologichttps://practicaldermatology.com/news/phase-2-psoriasis-study-shows-positive-results-for-boehringer-ingelheims-investigational-biologic/2458837/Results from a Phase II head-to-head psoriasis study show superior efficacy of Boehringer Ingelheim’s investigational biologic compound BI 655066 over ustekinumab. After nine months, 69 percent of patients with moderate-to-severe plaque psoriasis maintained PASI 90 with BI 655066, compared
- One Quarter of Americans Misled by Online Info: Surveyhttps://practicaldermatology.com/news/one-quarter-of-americans-misled-by-online-info-survey/2458841/One in four Americans (24 percent) say they have been misled by information about an illness or medical symptom from an unverified online source, according to a new survey from Merck Manuals. That figure increases to 30 percent among parents with children under 18 and jumps to 43 percent among mi
- OHSU Releases Mole Mapper App to Track Potential Skin Cancershttps://practicaldermatology.com/news/ohsu-releases-mole-mapper-app-to-track-potential-skin-cancers/2458843/Oregon Health & Science University released an iPhone app it says is designed to advance melanoma research by giving users the ability to accurately measure and monitor moles, and contribute photos of how their potential trouble spots evolve over time. Called Mole Mapper, the app is free to d
- RXi Pharmaceuticals Announces Positive Interim Results in Phase 2a Dermatology Program with RXI-109https://practicaldermatology.com/news/rxi-pharmaceuticals-announces-positive-interim-results-in-phase-2a-dermatology-program-with-rxi-109/2458844/RXi Pharmaceuticals Corporation shared results from a blinded panel and an Investigator review showing that incision sites treated with RXI-109 after scar revision surgery achieved better scores as compared to control incision sites in the same subjects, three months post scar revision surgery.</
- MELA Sciences Announces Election of R. Rox Anderson, MD, to Board of Directorshttps://practicaldermatology.com/news/mela-sciences-announces-election-of-r-rox-anderson-md-to-board-of-directors/2458845/R. Rox Anderson, M.D., was elected to the MELA Sciences, Inc.’s board of directors at its Annual General Meeting of Stockholders held on September 30, 2015 in Philadelphia. With Dr. Anderson's election, the MELA board of directors has increased to seven members, six of whom are independ
- FDA Accepts sNDA for Dalvancehttps://practicaldermatology.com/news/fda-accepts-snda-for-dalvance/2458849/The FDA accepted Allergan's supplemental New Drug Application (sNDA) to expand the label to include single-dose administration of DALVANCE® (dalbavancin) for the treatment of acute bacterial skin and skin structure infections (ABSSSI) in adults caused by design